Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Stefan Hubert Boeck

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1922-2127; OpenAlex author ID A5031266401. Sources: OpenAlex.

Their work

Papers
87 (first author 11, last author 22)
Trials
0
Grants
0
Labs led
1
Collaborators
190
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 12 papers · 2014: 7 papers · 2015: 2 papers · 2016: 4 papers · 2017: 8 papers · 2018: 7 papers · 2019: none · 2020: 4 papers · 2021: 5 papers · 2022: 8 papers · 2023: 8 papers · 2024: 6 papers · 2025: 7 papers · 2026: 4 papers

Papers 50 of 87

  1. Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2026.117040↗
  2. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Co-author DOI 10.1016/j.esmogo.2025.100274↗
  3. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  4. Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic Cancer. Co-author DOI 10.3390/cells15060527↗
  5. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  6. Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
  7. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
  8. Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches. Co-author DOI 10.1158/2159-8290.cd-23-1480↗
  9. Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs,… Co-author DOI 10.1158/2326-6066.cir-24-0299↗
  10. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  11. The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer. Co-author DOI 10.3390/biom15030426↗
  12. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Co-author DOI 10.1007/s12094-023-03323-1↗
  13. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Co-author DOI 10.1016/j.ejca.2024.113926↗
  14. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Co-author DOI 10.1016/j.esmoop.2024.102944↗
  15. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  16. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  17. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… First author DOI 10.1016/s2468-1253(24)00197-3↗
  18. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
  19. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  20. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… First author DOI 10.1016/j.ejca.2022.12.009↗
  21. TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02295-x↗
  22. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
  23. Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. Co-author DOI 10.1159/000528722↗
  24. Exploring Pain, Quality of Life, and Emotional Well-Being in Patients with Advanced Pancreatic Cancer Practicing Spiritual Meditation: A Pilot Study. Co-author DOI 10.1159/000529865↗
  25. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… First author DOI 10.3390/curroncol30060436↗
  26. The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. First author DOI 10.1002/ijc.34044↗
  27. [Treatment of metastatic pancreatic cancer]. First author DOI 10.1007/s00108-022-01334-8↗
  28. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Last author DOI 10.1016/j.esmoop.2022.100388↗
  29. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  30. Novel systemic treatment approaches for metastatic pancreatic cancer. Last author DOI 10.1080/13543784.2022.2037552↗
  31. Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac039↗
  32. Comment on: "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis". Co-author DOI 10.1097/sla.0000000000005405↗
  33. Preanalytical Variables in the Analysis of Mitochondrial DNA in Whole Blood and Plasma from Pancreatic Cancer Patients. Co-author DOI 10.3390/diagnostics12081905↗
  34. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  35. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Last author DOI 10.1007/s12094-021-02620-x↗
  36. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of… Co-author DOI 10.1016/j.ejca.2020.12.029↗
  37. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  38. Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers13225732↗
  39. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Last author DOI 10.1007/s00432-019-03061-4↗
  40. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  41. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… Co-author DOI 10.1038/s41416-020-01029-7↗
  42. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  43. POLE gene hotspot mutations in advanced pancreatic cancer. Co-author DOI 10.1007/s00432-018-2746-x↗
  44. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Co-author DOI 10.1007/s11523-018-0578-x↗
  45. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Last author DOI 10.1016/j.ejca.2018.02.008↗
  46. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  47. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  48. Sequence therapy in metastatic pancreatic cancer. Co-author DOI 10.1055/a-0581-5640↗
  49. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdy417↗
  50. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. Last author DOI 10.1016/j.thromres.2017.06.021↗

Closest collaborators

The 25 strongest of 190 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volker Heinemann · 74 shared papers, 2011–2026 · strength 7.48
  2. Michael Haas · 50 shared papers, 2012–2026 · strength 4.53
  3. Steffen Ormanns · 36 shared papers, 2013–2026 · strength 3.76
  4. Stephan Krüger · 32 shared papers, 2014–2025 · strength 2.72
  5. Christoph Benedikt Westphalen · 21 shared papers, 2016–2024 · strength 2.30
  6. Jens Werner · 19 shared papers, 2016–2025 · strength 2.26
  7. Jens Thomas Siveke · 17 shared papers, 2013–2026 · strength 1.92
  8. Klara Dorman · 10 shared papers, 2022–2026 · strength 1.72
  9. Dirk Waldschmidt · 12 shared papers, 2013–2026 · strength 1.61
  10. Michael Guenther · 9 shared papers, 2018–2026 · strength 1.57
  11. Volker Kunzmann · 10 shared papers, 2018–2026 · strength 1.52
  12. Danmei Zhang · 9 shared papers, 2023–2026 · strength 1.50
  13. Anke Reinacher‐Schick · 10 shared papers, 2012–2026 · strength 1.32
  14. Thomas Jens Ettrich · 9 shared papers, 2018–2026 · strength 1.23
  15. Frank Kullmann · 9 shared papers, 2013–2026 · strength 1.16
  16. Julia V. Mayerle · 9 shared papers, 2018–2024 · strength 1.07
  17. Stefan Holdenrieder · 12 shared papers, 2013–2026 · strength 1.01
  18. Brigitte Kimmel · 5 shared papers, 2022–2026 · strength 0.96
  19. Lena Weiss · 6 shared papers, 2023–2024 · strength 0.95
  20. Sai Agash Surendran · 4 shared papers, 2022–2026 · strength 0.88
  21. Hana Algül · 6 shared papers, 2020–2026 · strength 0.83
  22. Uwe Pelzer · 7 shared papers, 2018–2024 · strength 0.81
  23. Helmut Oettle · 5 shared papers, 2021–2026 · strength 0.78
  24. Ingo Hartlapp · 5 shared papers, 2021–2026 · strength 0.76
  25. Uwe M. Martens · 5 shared papers, 2021–2026 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.